{"entity":{"id":"idp-002","kind":"drug","name":"IDP-002","aka":[],"tldr":"IDP-002 is an experimental bispecific PD-1 antagonist from InduPro Therapeutics, in preclinical development for cancer.","summary":"IDP-002 is a bispecific PD-1 antagonist from InduPro Therapeutics. A bispecific PD-1 antagonist that binds PD-1 together with an undisclosed T-cell antigen for cooperative binding; the company says it does not depend on VEGF. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Listed under Immuno-Oncology; pipeline chart bar in the lead-optimisation column (HTML data-width 48); no registered trial found. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"InduPro Therapeutics: induprotx.com","url":"https://www.induprotx.com/pipeline"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":[],"companies":["indupro-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"IDP-002","modality":"Bispecific PD-1 antagonist","mechanism":"A bispecific PD-1 antagonist that binds PD-1 together with an undisclosed T-cell antigen for cooperative binding; the company says it does not depend on VEGF.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/idp-002/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"indupro-therapeutics","kind":"company","name":"InduPro Therapeutics","route":"/companies/indupro-therapeutics/"}]}}